Psych Congress NetworkSynthetic Psilocybin Meets Primary Endpoint in Phase 3 Treatment-Resistant Depression Trial

COMP360 psilocybin 25 mg met its primary endpoint in COMP006, a 581-patient Phase 3 RCT, reducing MADRS scores by 3.8 points vs. 1 mg control (p<0.001) at week 6. An estimated 4 million US adults with TRD have exhausted standard options, making this the most significant pipeline development in treatment-resistant depression in years.

🧠 Clinical Considerations

• Rapid onset within 24 hours of dosing sustained through week 6, a profile no current antidepressant class matches
• 39% of patients achieved clinically meaningful 25% MADRS reduction with just two doses, 3 weeks apart
• Serious adverse events in only 2% of 25 mg participants; 83-88% of TEAEs resolved within 24 hours
• Suicidal ideation under 1% across both trials, reassuring for psychiatrists managing this high-risk population

🎯 Practice Applications

• Identify patients with two or more failed adequate antidepressant trials now for future eligibility tracking
• Document current MADRS baselines to establish pre-treatment comparators before therapy becomes available
• Counsel patients that hallucinations and anxiety are expected, transient, dosing-day effects and not a cause for alarm
• Monitor FDA NDA timeline; Compass targets submission by end of 2026

More on Psychedelics